Diversified Consumer Services
Company Overview of University of Cambridge
University of Cambridge is an educational institution that offers graduate, postgraduate, and research programs in the field of science, business, social sciences, and law. It offers courses in history, environmental studies, psychology, sociology, zoology, oriental studies, business administration, philosophy, biochemistry, music, engineering, geology, architecture, international relations, and medicine. The institution was founded in 1209 and is based in Cambridge, United Kingdom.
The Old Schools
Cambridge, CB2 1TN
Founded in 1209
Key Executives for University of Cambridge
Regius Professor of Physic
Master of Pembroke College
Head of Institute for Stem Cell Biology
Compensation as of Fiscal Year 2015.
University of Cambridge Key Developments
DefiniGEN Announces Licensing Agreement with University of Cambridge
Aug 12 15
DefiniGEN Ltd. has licensed lung stem cell technology from University of Cambridge. DefiniGEN will use the technology to develop cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis.
University of Cambridge Presents at Credit Suisse 6th Annual European Pensions Strategy Conference, Apr-23-2015 09:30 AM
Apr 11 15
University of Cambridge Presents at Credit Suisse 6th Annual European Pensions Strategy Conference, Apr-23-2015 09:30 AM. Venue: Credit Suisse, 20 Columbus Courtyard, Canary Wharf, London E14 4DA, United Kingdom. Speakers: Elroy Dimson.
H. Lundbeck A/S Announces Research Partnership for Treatment of Brain Diseases Involving Seven Universities
Jan 9 15
H. Lundbeck A/S has announced a new public-private partnership involving seven universities, for the treatment of brain diseases. Lundbeck is involved in new research that will investigate a novel link that could show a relationship between the immune system and mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer's disease. This project, a public-private partnership also involving The Wellcome Trust, Cambridge University and pharmaceutical company Janssen, may be the first step towards a new and significantly improved treatment for a broad range of brain diseases. The main theory that the project will investigate is that the immune system can worsen brain diseases like depression and Alzheimer's disease. An imbalance in the immune system of the brain can drive a permanent and unhealthy neuro-inflammation - or inflammation in the brain - that can contribute to or cause brain diseases. This new project is a public-private partnership between Lundbeck and Janssen, and seven universities. The project has received a strategic award valued at approximately DKK 50m from the Wellcome Trust. The project consists of two parts. The team will begin by investigating the immune systems of people with treatment-resistant depression and Alzheimer's disease. In this phase, researchers will seek to more precisely establish the relationship between immune-related biomarkers found in blood and brain including cytokines, which are small proteins that play an important role in the regulation of the immune responses. The second part of the research program, which is reliant on the success of the first, will focus on small experimental medicine trials, using re-purposed anti-inflammatory drugs in patients who have been identified according to their specific immunological profile or 'phenotype'.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|